VIDEO: Large real-world study 'reassuring' for brexu-cel for mantle cell lymphoma
Click Here to Manage Email Alerts
In this video, Jakub Svoboda, MD, discusses the results of a large real-world study on brexu-cel for mantle cell lymphoma, which were presented at ASCO Annual Meeting.
The study looked at real-world data on outcomes after treatment with the anti-CD19 chimeric antigen receptor (CAR) T-cell therapy brexucabtagene autoleucel (Tecartus, Kite Pharma), also known as brexu-cel.
“The findings were reassuring,” Svoboda, associate professor of medicine at the Hospital of the University of Pennsylvania, said.
The overall response rate was 89%, while the complete response (CR) rates were similar to those found in the ZUMA-2 trial, he said.
“One important finding is that ... the earlier you use brexu-cel, the better the CR rate may be,” he said. “This suggests that using the CAR-T earlier in the course of the disease may work better," he said.
Reference :
- Kambhampati S, et al. Abstract 7507. Presented at: ASCO Annual Meeting; June 2-6, 2023; Chicago.
Collapse
Healio Interviews
Read more about
Click Here to Manage Email Alerts